Compare Quest Diagnostics Inc (DGX) vs Hyatt Hotels Corporation (H) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Hyatt Hotels Corporation — how do they compare? Quest Diagnostics Inc trades at $237.17 (market cap $26.21B), while Hyatt Hotels Corporation trades at $175.8 (market cap $16.27B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.45%). Which is the better fit depends on your goals.
| DGX | H | |
|---|---|---|
Market Cap | $26.21B | $16.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $202.09 |
52-Week Low | $173.49 | $135.42 |
Enterprise Value | $31.97B | $20.17B |
Dividend Yield | 1.45% | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Hyatt Hotels Corp (H) trades at $170.08, down 4.29% on the day, reflecting a bearish technical trend with key support at $167. Fundamentally, the company shows revenue growth to $7.10B in 2025 but reported a net loss of $52M, with a high P/E ratio of 213.14 indicating premium valuation. Recent Q2 2026 earnings beat expectations with EPS of $1.12, driven by strong fee growth and RevPAR gains, as reported by Business Wire on July 30, 2026.
The outlook is mixed; analyst consensus is a 'Hold' with a $199.55 price target, suggesting 17% upside, but high debt and regional weaknesses pose risks. Investment opportunity hinges on sustained operational momentum offsetting valuation concerns, with key risks including project delays and macroeconomic pressures on travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →
